JP2011521897A5 - - Google Patents

Download PDF

Info

Publication number
JP2011521897A5
JP2011521897A5 JP2011505127A JP2011505127A JP2011521897A5 JP 2011521897 A5 JP2011521897 A5 JP 2011521897A5 JP 2011505127 A JP2011505127 A JP 2011505127A JP 2011505127 A JP2011505127 A JP 2011505127A JP 2011521897 A5 JP2011521897 A5 JP 2011521897A5
Authority
JP
Japan
Prior art keywords
peptide ligand
moiety
nanoparticle
fluorescent
ligand according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011505127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011521897A (ja
JP5497006B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/040480 external-priority patent/WO2009129220A2/en
Publication of JP2011521897A publication Critical patent/JP2011521897A/ja
Publication of JP2011521897A5 publication Critical patent/JP2011521897A5/ja
Application granted granted Critical
Publication of JP5497006B2 publication Critical patent/JP5497006B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011505127A 2008-04-14 2009-04-14 膵管腺癌の検出および治療のためのプレクチン−１標的化剤 Active JP5497006B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4481808P 2008-04-14 2008-04-14
US61/044,818 2008-04-14
PCT/US2009/040480 WO2009129220A2 (en) 2008-04-14 2009-04-14 Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014042379A Division JP6046070B2 (ja) 2008-04-14 2014-03-05 膵管腺癌の検出および治療のためのプレクチン−１標的化剤

Publications (3)

Publication Number Publication Date
JP2011521897A JP2011521897A (ja) 2011-07-28
JP2011521897A5 true JP2011521897A5 (enExample) 2012-07-05
JP5497006B2 JP5497006B2 (ja) 2014-05-21

Family

ID=41199683

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011505127A Active JP5497006B2 (ja) 2008-04-14 2009-04-14 膵管腺癌の検出および治療のためのプレクチン−１標的化剤
JP2014042379A Active JP6046070B2 (ja) 2008-04-14 2014-03-05 膵管腺癌の検出および治療のためのプレクチン−１標的化剤
JP2016223323A Pending JP2017048239A (ja) 2008-04-14 2016-11-16 膵管腺癌の検出および治療のためのプレクチン−１標的化剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014042379A Active JP6046070B2 (ja) 2008-04-14 2014-03-05 膵管腺癌の検出および治療のためのプレクチン−１標的化剤
JP2016223323A Pending JP2017048239A (ja) 2008-04-14 2016-11-16 膵管腺癌の検出および治療のためのプレクチン−１標的化剤

Country Status (6)

Country Link
US (4) US8829159B2 (enExample)
EP (2) EP2265630B1 (enExample)
JP (3) JP5497006B2 (enExample)
CA (1) CA2758415C (enExample)
HK (1) HK1209438A1 (enExample)
WO (1) WO2009129220A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2265630B1 (en) * 2008-04-14 2014-10-29 The General Hospital Corporation Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma
US9075059B2 (en) * 2009-11-05 2015-07-07 University Of Virginia Patent Foundation Compositions and methods for detecting plectin-1 as a biomarker for cancer
DE102010039289A1 (de) * 2010-08-12 2012-02-16 Leica Microsystems (Schweiz) Ag Mikroskopsystem
EP2776587A4 (en) * 2011-11-10 2015-07-15 Exosome Diagnostics Inc LIQUOR ASSAY
WO2013109944A1 (en) * 2012-01-18 2013-07-25 The Trustees Of The University Of Pennsylvania Methods for assessing risk for cancer using biomarkers
US10860526B2 (en) * 2012-12-01 2020-12-08 The Regents Of The University Of California System and method of managing large data files
US9606123B2 (en) 2013-03-29 2017-03-28 University Of Virginia Patent Foundation Compositions and methods for diagnosing and monitoring ovarian cancer progression and treatment
US20160166715A1 (en) * 2013-07-30 2016-06-16 Tarveda Therapeutics, Inc. Nanoparticle Diagnostic and Methods for Treating Disease
US10182791B2 (en) * 2013-10-07 2019-01-22 The Regents Of The University Of California Integrated ultrasound, OCT, PA and/or florescence imaging endoscope for diagnosing cancers in gastrointestinal, respiratory, and urogenital tracts
JP6812004B2 (ja) * 2015-11-19 2021-01-13 国立大学法人 新潟大学 膵癌に特異的な集積性を有するペプチド及びその使用
US10611796B2 (en) * 2016-03-16 2020-04-07 Council Of Scientific & Industrial Research Method for regressing pancreatic tumor by a liposomal formulation along with DNA vaccines
KR102611444B1 (ko) * 2016-04-08 2023-12-06 지엘바이오, 인크. 플렉틴-1 결합 항체 및 그의 용도
AU2017252015A1 (en) * 2016-04-19 2018-11-08 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
CN109963875A (zh) * 2016-10-26 2019-07-02 西尔欧集团 靶向并通过辐射能分解癌症的癌症结合不透射线肽类
WO2018227112A1 (en) 2017-06-09 2018-12-13 The Trustees Of Columbia University In The City Of New York Short tat oligomers for drug delivery
WO2019075216A1 (en) * 2017-10-11 2019-04-18 Iti Health, Inc. D/B/A Zielbio ANTIBODIES BINDING TO PELTIN-1 AND USES THEREOF
CA3081925A1 (en) 2017-11-18 2019-05-23 Nzola DE MAGALHAES Product and process for employing gc7 (n1-guanyl-1,7-diaminoheptane) based antigen binding conjugates in cancer therapy
WO2019168921A1 (en) * 2018-02-27 2019-09-06 University Of Virginia Patent Foundation Plectin-targeted liposomes/parp inhibitor in the treatment of cancer
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
EP3895733A4 (en) * 2018-12-14 2022-03-02 Konica Minolta, Inc. METHOD OF PREDICTING THE ARRIVAL OF A DRUG WITHIN DISEASED TISSUE
CN115651063A (zh) * 2022-03-29 2023-01-31 上海市第一人民医院 放射性核素标记的ptp多肽及其应用
CN114814200B (zh) * 2022-05-09 2025-06-27 浙江大学 一种纳米颗粒-荧光标记融合蛋白复合体及其单链dna检测方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3307869A1 (de) 1983-03-05 1984-09-06 Dragoco Gerberding & Co Gmbh, 3450 Holzminden Methylsubstituierte 1-((3-methylthio)-1-oxo-butyl)-cyclohex-2-ene, verfahren zu deren herstellung und deren verwendung als riech- und aromastoffe
EP0335476A3 (en) 1984-02-08 1989-12-13 Cetus Corporation Recombinant methods for the production of ricin a, ricin b, ricin or diphtheria toxin (dt)a or ab' fragment, suitable hosts and vectors therefor, and conjugates comprising ricin toxin a chain or diphtheria toxin
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
JP2594123B2 (ja) 1987-09-12 1997-03-26 株式会社林原生物化学研究所 減感作剤
US5827934A (en) 1988-03-08 1998-10-27 The University Of Wyoming Cytotoxic diphtheria toxin fragments
US5169862A (en) 1989-07-07 1992-12-08 Peptide Technologies Corporation Analogs of viscosin and their uses
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
IL98744A0 (en) 1990-07-06 1992-07-15 Gen Hospital Corp Method of studying biological tissue using monocrystalline particles
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
CN1124927A (zh) 1993-03-29 1996-06-19 辛辛那提大学 Yy肽类似物及其应用
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5539085A (en) 1993-08-20 1996-07-23 Onyx Pharmaceuticals, Inc. Bcl-2 and R-ras complex
US5696093A (en) 1994-10-28 1997-12-09 Crc For Biopharmaceutical Research Pty Limited Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
ATE264694T1 (de) 1995-01-30 2004-05-15 Daiichi Pure Chemicals Co Ltd Diagnostisches markierungsmittel
US20030100051A1 (en) * 1998-05-12 2003-05-29 Ruben Steven M. 97 human secreted proteins
DE19717904A1 (de) 1997-04-23 1998-10-29 Diagnostikforschung Inst Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
US6592847B1 (en) 1998-05-14 2003-07-15 The General Hospital Corporation Intramolecularly-quenched near infrared flourescent probes
US20030103975A1 (en) * 1999-11-03 2003-06-05 Jones Jonathan C.R. Modulation of angiogenesis and endothelialization
US20030069180A1 (en) * 2000-06-09 2003-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20020177207A1 (en) * 2001-03-14 2002-11-28 Myriad Genetics, Incorporated Tsg101-interacting proteins and use thereof
AUPR290801A0 (en) 2001-02-06 2001-03-01 Peter Maccallum Cancer Institute, The Substrate binding domain
US20030092029A1 (en) * 2001-06-06 2003-05-15 Lee Josephson Magneitc-nanoparticle conjugates and methods of use
WO2003030725A2 (en) 2001-10-11 2003-04-17 The Johns Hopkins University Pancreatic cancer diagnosis and therapies
AU2003228418A1 (en) * 2002-03-29 2003-10-13 The General Hospital Corporation Nir-fluorescent cyanine dyes, their synthesis and biological use
US20040018622A1 (en) * 2002-07-17 2004-01-29 Mitchell Lloyd G. Spliceosome mediated RNA trans-splicing for correction of skin disorders
AU2002951346A0 (en) * 2002-09-05 2002-09-26 Garvan Institute Of Medical Research Diagnosis of ovarian cancer
US20050260639A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
JP2006516262A (ja) 2002-12-17 2006-06-29 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド Ｙ２受容体結合ペプチドの粘膜送達促進のための組成物および方法ならびに肥満症の治療法および予防法
US20050095611A1 (en) 2003-05-02 2005-05-05 Chan Daniel W. Identification of biomarkers for detecting pancreatic cancer
WO2005117977A2 (en) * 2004-06-02 2005-12-15 Sidney Kimmel Cancer Center Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface
EP1877428B1 (en) * 2005-04-22 2011-03-16 University of Washington Cyanine- chlorotoxin conjugate and method for intra-operative visualization of cancer
EP2005187A4 (en) * 2006-03-23 2010-04-21 Life Technologies Corp METHOD AND REAGENTS FOR IN VIVO IMAGING CANCER CELL LINES
CA2699794C (en) 2007-09-10 2016-07-19 University Of Massachusetts Mitochondria-targeted anti-tumor agents
EP2265630B1 (en) * 2008-04-14 2014-10-29 The General Hospital Corporation Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma
US8802738B2 (en) * 2008-12-12 2014-08-12 University Of Massachusetts Polyesters with grafted zwitterions

Similar Documents

Publication Publication Date Title
Nguyen et al. Recent progress and challenges of MOF-based nanocomposites in bioimaging, biosensing and biocarriers for drug delivery
Liu et al. Melanin‐like nanomaterials for advanced biomedical applications: a versatile platform with extraordinary promise
JP6510494B2 (ja) 腎薬物標的化のためのペプチドおよびペプチド−活性成分の接合体
Hong et al. In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nano-graphene
Kim et al. Tumor targeting and imaging using cyclic RGD‐PEGylated gold nanoparticle probes with directly conjugated iodine‐125
Guerrero et al. Synthesis and in vivo evaluation of the biodistribution of a 18F-labeled conjugate gold-nanoparticle-peptide with potential biomedical application
AU2015247833B2 (en) Bi-terminal PEGylated integrin-binding peptides and methods of use thereof
CN114340610A (zh) 多价成纤维细胞靶向剂及使用方法
JP2015530404A5 (enExample)
Um et al. A comparative study on albumin-binding molecules for targeted tumor delivery through covalent and noncovalent approach
CN102438656A (zh) 预靶向试剂盒、方法和其中使用的试剂
Rizvi et al. Engineering peptide drug therapeutics through chemical conjugation and implication in clinics
Liu et al. An integrative folate-based metal complex nanotube as a potent antitumor nanomedicine as well as an efficient tumor-targeted drug carrier
Hou et al. Advancements and challenges in the application of metal-organic framework (MOF) nanocomposites for tumor diagnosis and treatment
Duan et al. Advanced diagnostic and therapeutic strategies in nanotechnology for lung cancer
Zhu et al. Developing a hetero-trinuclear erbium (III)–copper (II) complex based on apoferritin: targeted photoacoustic imaging and multimodality therapy of tumor
Rajasekharreddy et al. Green synthesized nanomaterials as theranostic platforms for cancer treatment: Principles, challenges and the road ahead
KR20140012112A (ko) 테크네튬 표지화 펩티드
Wang et al. Recent progress in functional peptides designed for tumor-targeted imaging and therapy
CN110420337A (zh) 一种靶向整合素α6的二聚体多肽放射性药物及其制备方法
WO2016150521A1 (en) Functionalised magnetic nanoparticle
Vavsari et al. Technetium-99m-labeled peptides and their applications in radio imaging: advancements in Latin American research
Rerat et al. Ultrasmall particle of iron oxide—RGD peptidomimetic conjugate: synthesis and characterisation
Kaur et al. An Overview of Structural Framework and Classification of Theranostic Radiopharmaceuticals
JP6848015B2 (ja) 放射性元素の標識方法、放射性標識化合物、及びそれを含む放射性元素標識キット